CN1477127A - Anti-venerism specific compound vitelline antibody and its application for curing venerism - Google Patents
Anti-venerism specific compound vitelline antibody and its application for curing venerism Download PDFInfo
- Publication number
- CN1477127A CN1477127A CNA031396879A CN03139687A CN1477127A CN 1477127 A CN1477127 A CN 1477127A CN A031396879 A CNA031396879 A CN A031396879A CN 03139687 A CN03139687 A CN 03139687A CN 1477127 A CN1477127 A CN 1477127A
- Authority
- CN
- China
- Prior art keywords
- disease
- yolk antibody
- resistance
- specific composite
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a specific composite egg yolk antibody for resisting venereal disease. The antibody can be prepared by adopting the following processes: optimizing main pathogen resulting in venereal disease, preparing two kinds or more than two kinds of pathogens resulting in veneral disease; preparing immunology, preparing venerism-resisting pathogen specific yolk antibody crude product and purifying said crude product, mixing unique specific yolk antibodies according to the ratio so as to obtain the venerison-resisting specific composite yolk antibody. The invention also discloses its application of curing venereal disease.
Description
Technical field
The present invention relates to a kind of resistance disease-specific antibody, relate in particular to a kind of specificity compound antibody that is used to prevent and treat syphilis, gonorrhoea, pointed condyloma and genital herpes.The invention still further relates to the application of this compound antibody in treatment for the sexually transmitted diseases.
Background technology
Treatment syphilis is mainly used heavy dose of benzathine penicillin preparation, i.e. procaine penicillin or penicillin G both at home and abroad at present.As underdosage, the course of treatment is irregular, can increase the danger that tertiary syphilis takes place.The treatment gonorrhoea is mainly used antibiotic, but because gonorrhea diplococcus resistance occurs to a lot of microbiotic, the particularly appearance of penicillin resistant and anti-tsiklomitsin and other Resistant strain, penicillin and tsiklomitsin have not been re-used as the first line medicine of treatment gonorrhoea, replace treatments such as third generation cephalosporin, spectinomycin, quinlone class, azithromycin, but 6%～14% resistant organism appearance is still arranged.Pointed condyloma treatment be there is no definite curative effect medicine at present, mainly with surgical excision, electricity coagulate, psychrotherapy, CO
2Laser therapy etc., but all can't eradicate papovavirus, i.e. human papillomavirus (HPV).Genital herpes can make the state of an illness alleviate through general treatment or antiviral therapy, but Most patients can not be eradicated hsv (HSV).The more important thing is that the process of using above-mentioned treatment means can destroy vagina or the local microecological balance of male urethra, injustice has been killed harmful bacterium, has also killed normal microflora, as probioticss such as lactobacillus, coryneform bacteria, faecalis, non-Streptococcus hemolyticuss.Lactobacillus has makes vagina or the local effect that forms slightly acidic or low pH value of urethra, thereby suppresses the hypertrophy and the adhesion of other microorganism and virus.The breeding of other bacillus has promoted useful anerobe growth again, thereby has kept vagina or urethra normal microflora balance from the pros and cons, and is very useful to strengthening immunity.Use the antibiotic therapy venereal disease not only to produce Resistant strain, also will kill probioticss such as lactobacillus, destroy the normal microflora balance, make vagina or urethra lose the barrier of original natural defence disease, increase the weight of the state of an illness on the contrary.At present above-mentioned multiple venereal disease still there are not medicine ideal, environmental protection, that have no side effect or means both at home and abroad.
Summary of the invention
The object of the present invention is to provide a kind of specificity composite yolk antibody that can directly suppress the common venereal diseases pathogenic agent.
Another object of the present invention provides the application of this composite yolk antibody in treatment for the sexually transmitted diseases.
Resistance disease-specific composite yolk antibody of the present invention can be prepared by following method: (A) preferably cause the main pathogenic bacterium of venereal disease, preparation causes several main single pathogenic agent that cause venereal disease of venereal disease; (B) prepare immune egg; (C) prepare resistance disease pathogen body special yolk antibody crude product, and crude product is carried out purifying; (D) single special yolk antibody is prepared by a certain percentage resistance disease-specific composite yolk antibody.
Wherein, steps A is according to the epidemiology survey situation, and screening causes the pathogenic agent of venereal disease, prepares the single pathogenic agent that causes venereal disease respectively as antigen, breeds in a large number, collects culture, purifies the dilution packing; The various single venereal disease pathogenic agent that cause are added freund adjuvant, pulverize and make milk-like slurry, make the pathogenic former isoantigen of single venereal disease.
Step B selects to have the bird inlay that the healthy no-special pathogen that facing out of high immunne response ability produces or laying eggs carries, the single venereal disease antigen of chest muscle or subcutaneous injection.
The step C not immune respectively hen of synantigen produces the egg categorised collection, with 0.5% bromogeramine solution or 0.1%KMnO4 solution or similar thimerosal immune egg is soaked sterilization in 15～30 minutes, put in the beating machiae, filtering egg white stays yolk and adds 4～8 times of distilled water dilutings, transfer PH to 5.5～6.0,4 ℃ of following standing over night, centrifugal, and concentrate drying obtains resistance disease-specific yolk antibody crude product.With crude product ion exchange column and gel exchange column purifying.
Step D be with multiple single specific yolk antibody in 1～10: 1～10: 1～10: 1～10 ratio uniform mixing, make resistance disease-specific composite yolk antibody.
When resistance disease-specific composite yolk antibody is applied in the treatment of venereal disease, above-mentioned resistance disease-specific composite yolk antibody is made washing lotion; Also can be made into the sick sprays of resistance; Also can be made into the sick ointment of resistance; Also can be made into the sick effervescent tablet of resistance.
Resistance disease-specific composite yolk antibody of the present invention belongs to the IgG immunoglobulin like protein, and is main with the immune breeding hens of four kinds of pathogenic agent that cause syphilis, gonorrhoea, pointed condyloma and genital herpes, makes it a large amount of corresponding immunoglobulin (Ig)s of generation, makes.This compound antibody has specificity combination and restraining effect to the pathogenic agent that causes syphilis, gonorrhoea, pointed condyloma and genital herpes.Because it only plays treatment and restraining effect to the focus pathogenic agent and the symbiosis probiotics is forbidden the slightest violation of the people's interests, and can not destroy the microecological balance of lesions position, this prevents and treats the precedent that the venereal disease aspect is an initiative at home and abroad.The specificity compound antibody is equipped with certain auxiliary material and makes the sick washing lotion of various resistances, sprays, gelifying agent, ointment etc.Above formulation is directly imposed on the most concentrated positions of pathogenic agent such as vulva, vagina, uterine cervix, glans penis, the infective pathogen body directly can be killed, effective, instant effect, solved conventional oral or the injection make medicine enter various untoward reactions and the toxic side effect that is produced after the human circulation.Simultaneously, also can remove the misery that brings the patient because of surgical interventions such as excision, laser therapies.Because the present invention is the biotechnological formulation of a specific specificity, pure natural, its mechanism of action is the human body passive immunization, safety and environmental protection, can be as not using microbiotic or chemical disinfection medicine pathogenic bacterium and probiotics do not killed together and destroy microecological balance, or cause the pathogenic agent resistance, reach and not only cure the disease but also the dual function of prevention and health care.
Embodiment
Embodiment one
The preparation 1 of composite yolk antibody, preferably cause representational pathogenic agent common, multiple venereal disease.
Select Treponoma palladium, gonorrhea diplococcus, human papillomavirus and hsv (HSV-2) as representational venereal disease pathogenic agent according to the epidemiology survey result.2, antigen prepd.
Choose commercially available Treponoma palladium, gonorrhea diplococcus, human papillomavirus and hsv (HSV-2) type strain, respectively by its cultural characters and optimal culture conditions, select the suitable culture base to cultivate in a large number and breed with ordinary method, collect culture, purify, count, dilute packing then.3, select to have the bird of laying eggs (comprising bird inlay, duck, female goose, turkey and ostrich etc.) that the healthy no-special pathogen of high immunne response ability carries and carry out reinforced immunological.
Every health is laid eggs bird at chest muscle or the above-mentioned antigen that makes of subcutaneous injection, and in injection the last for the first time 7 days at interval, again with same dosage, method injection for the second time, 7 days with the same dose injection for the third time at interval again after the injection for the second time.The injection back was chosen since the 20th day and is got high immune egg for the first time.
Make pathogenic agent liquid with each 1,000,000,000 counting of Treponoma palladium, gonorrhea diplococcus, human papillomavirus and hsv respectively, put in the high-speed homogenization machine, with the homogenize of 10000～30000rpm high speed, promptly make four kinds of antigens of Treponoma palladium, gonorrhea diplococcus, human papillomavirus and hsv (HSV-2), add the abundant mixing of freund adjuvant with 1: 1 ratio respectively again, respectively make 1ml.4, immune egg is collected and the preparation of special yolk antibody crude extract.
With 0.5% bromogeramine solution or 0.1%KMnO
4Solution or other similar thimerosal soak sterilization in 15～30 minutes with immune egg, sterile distilled water washes, dries, put in the beating machiae eggshell is smashed, remove egg white with the yolk sieving and stay yolk, adding 4～8 times of distilled water dilutings stirs, regulate pH to 5.5～6.0 with the NaOH of 1mol/L concentration or the HCL solution of 1mol/L concentration, 4 ℃ of following standing over night, dilution was with 10000～30000rpm high speed centrifugation 30 minutes, get the supernatant liquor ultrafiltration, the molecular weight cut-off that ultra-filtration membrane is selected for use is about 180,000 DW, 10～20 times of ultrafiltration and concentration.Concentrated solution is done with the freeze-drying spray and is promptly got four kinds of antiveneral special yolk antibody immunoglobulin (Ig) crude products.
The pure product preparation of special yolk antibody adopts ion exchange column and gel exchange column to carry out purifying, promptly makes yolk antibody sphaeroprotein pure white, and the content through record yolk antibody with the SDS-PAGE electrophoresis surpasses 50%.
With the Treponoma palladium is to detect antigen, records anti-syphilis specific yolk antibody in conjunction with tiring result such as following table with euzymelinked immunosorbent assay (ELISA):
| Yolk antibody | Detection antigen | Antibodies is tired |
| Anti-Treponoma palladium special yolk antibody (0.1% concentration) | Treponoma palladium | ??1∶1024 |
Find out that from above detected result the prepared anti-Treponoma palladium special yolk antibody of the present invention has very strong combination and resistancing action to syphilis infective pathogen body, detected antibodies is tired very good.
With the gonorrhea diplococcus is to detect antigen, records anti-gonorrhea diplococcus special yolk antibody in conjunction with tiring result such as following table with euzymelinked immunosorbent assay (ELISA):
| Yolk antibody | Detection antigen | Antibodies is tired |
| Anti-gonorrhea diplococcus special yolk antibody (0.1% concentration) | Gonorrhea diplococcus | ??1∶1024 |
Find out that from above detected result the prepared anti-gonorrhea diplococcus special yolk antibody of the present invention has very strong combination and resistancing action to the pathogenic bacterium that cause gonorrhoea, detected antibodies is tired very good.
With the human papillomavirus is to detect antigen, records the anti-human papilloma virus (anti-HPV) special yolk antibody in conjunction with tiring result such as following table with euzymelinked immunosorbent assay (ELISA):
| Yolk antibody | Detection antigen | Antibodies is tired |
| Anti-human papilloma virus (anti-HPV) special yolk antibody (0.1% concentration) | Human papillomavirus | ??1∶1024 |
Find out that from above detected result the prepared anti-human papilloma virus (anti-HPV) special yolk antibody of the present invention has very strong combination and resistancing action to the infective pathogen body that causes pointed condyloma, detected antibodies is tired very good.
With the hsv is to detect antigen, records the anti-herpes simplex virus special yolk antibody in conjunction with tiring result such as following table with euzymelinked immunosorbent assay (ELISA):
| Yolk antibody | Detection antigen | Antibodies is tired |
| Anti-herpes simplex virus special yolk antibody (0.1% concentration) | ????HSV-1 | ??1∶256 |
| ????HSV-2 | ??1∶1024 |
Find out that from above detected result the prepared anti-herpes simplex virus special yolk antibody of the present invention has very high antibodies to tire to the HSV-2 as antigen immune, prompting has the good restraining effect; Not direct of the same race veriform HSV-1 as antigen immune also there is certain restraining effect.So this experiment has strengthened HSV-2 as immunogenic feasibility.5, the sick composite yolk antibody of preparation resistance.
Get above-mentioned anti-Treponoma palladium yolk antibody lyophilized powder 250 grams, anti-gonorrhea diplococcus yolk antibody lyophilized powder 250 grams, anti-human papillomavirus's yolk antibody lyophilized powder 250 grams and anti-herpes simplex virus yolk antibody lyophilized powder 250 gram thorough mixing respectively, cross 80 mesh sieves, packing promptly gets resistance disease-specific composite yolk antibody lyophilized powder 1000 grams.
As detecting antigen, the antibodies that records resistance disease-specific composite yolk antibody with euzymelinked immunosorbent assay (ELISA) is tired, result such as following table with Treponoma palladium, gonorrhea diplococcus, human papillomavirus, hsv (HSV-2):
| Yolk antibody | Detection antigen | Antibodies is tired |
| Resistance disease-specific composite yolk antibody (0.15% concentration) | Treponoma palladium | ??1∶512 |
| Gonorrhea diplococcus | ??1∶512 | |
| Human papillomavirus | ??1∶256 | |
| Hsv (HSV-2) | ??1∶512 |
Find out with above-mentioned resistance disease-specific composite yolk antibody the infective pathogen body that directly causes venereal disease as antigen to be had quite high antibodies and tire from above result, reach the ideal effect.
Embodiment two
The preparation of resistance disease-specific composite yolk antibody washing lotion
Get resistance disease-specific composite yolk antibody lyophilized powder 150 grams of embodiment 1 preparation, allocate 100 liters of resistance disease-specific composite yolk antibody solution by following prescription:
Resistance disease-specific composite yolk antibody lyophilized powder 0.15%
Glycerine 1.5%
Eucalyptus oil 0.1%
Peppermint essence 0.1%
Fragrant citrus essence 0.1%
Borneol 0.1%
Ethanol 0.75%
Distilled water adds to 100 liters
Get 80 liters of distilled water earlier, add glycerine, composite yolk antibody stirring and dissolving then respectively; Eucalyptus oil, peppermint essence, fragrant citrus essence, the borneol of getting formula ratio again add the dissolve with ethanol of formula ratio, and under agitation slowly add in the aforementioned solution; Stir, adjust between pH value of solution value to 6.5～7.0, add distilled water to 100 liter at last, filter promptly.
Embodiment three
The preparation of resistance disease-specific composite yolk antibody sprays
Get resistance disease-specific composite yolk antibody lyophilized powder 100 grams of embodiment 1 preparation, allocate 100 liters of resistance disease-specific composite yolk antibody solution by following prescription:
Resistance disease-specific composite yolk antibody lyophilized powder 0.1%
Glycerine 0.1%
Peppermint essence 0.1%
Fragrant citrus essence 0.1%
Distilled water adds to 100 liters
Get 80 liters of distilled water earlier, add glycerine, composite yolk antibody stirring and dissolving then; Peppermint essence, fragrant citrus essence are dissolved in an amount of ethanol, under agitation slowly add in the aforementioned solution; Stir, adjust pH value of solution value to 6.5～7.0; Add distilled water to 100 liter at last, filter the back can in the spray bottle promptly.
Embodiment four
The preparation of resistance disease-specific composite yolk antibody ointment
Resistance disease-specific composite yolk antibody lyophilized powder 2%
Glycerine 11%
Octadecanoic acid 6.0%
Menthol 0.2%
Whiteruss 9.0%
White vaseline 6.0%
Span-80?????????????????????????????0.85％
Sorb potassium alcoholate 0.1%
Tween-80 4.5%
Distilled water adds to 100 liters
Oil phase and water are heated to 80 ℃ respectively, and water is slowly added in the oil phase, stir to be condensed to about 40 ℃, add composite yolk antibody solution, and fully grinding stirs makes water colour oil emulsifiable paste, promptly.
Embodiment five
The preparation of resistance disease-specific composite yolk antibody bubble rattan sheet (capsule)
Resistance disease-specific composite yolk antibody lyophilized powder 0.1%
Sodium bicarbonate 17%
Citric Acid, usp, Anhydrous Powder 15%
Boric acid 5%
Lactose 31%
Microcrystalline Cellulose 30%
Suds-stabilizing agent 0.4%
The 10%PVP dehydrated alcohol is an amount of
Magnesium Stearate 1%
Except that yolk antibody, boric acid, Magnesium Stearate, will steep rattan agent and other stone mixings routinely, with the granulation of PVP dehydrated alcohol, dry, whole grain, add composite yolk antibody and Magnesium Stearate, boric acid mixing, compressing tablet or filled capsules then.
Claims (10)
1, resistance disease-specific composite yolk antibody is characterized in that this antibody can be by the preparation of following method: (A) preferably cause the main pathogenic bacterium of venereal disease, preparation causes two or more the single pathogenic agent that causes venereal disease of venereal disease; (B) use the pathogenic agent of step (A) to prepare immune egg respectively; (C) prepare resistance disease pathogen body special yolk antibody crude product, and crude product is carried out purifying; (D) single special yolk antibody is mixed in proportion, it is compound to make the resistance disease-specific
Yolk antibody.
2, resistance disease-specific composite yolk antibody according to claim 1, it is characterized in that the antigen described in the step (A) is by the single pathogenic agent preparation that causes venereal disease and get, described cause of disease has four kinds, is respectively Treponoma palladium, gonorrhea diplococcus, human papillomavirus and hsv.
3, resistance disease-specific composite yolk antibody according to claim 2, it is characterized in that step (D) be with multiple single specific yolk antibody in 1～10: 1～10: 1～10: 1～10 ratio uniform mixing, make resistance disease-specific composite yolk antibody.
4, resistance disease-specific composite yolk antibody according to claim 3, it is characterized in that step (D) be with multiple single specific yolk antibody in 1: 1: 1: 1 ratio uniform mixing, make resistance disease-specific composite yolk antibody.
5, the application of the resistance disease-specific composite yolk antibody of the arbitrary claim of claim 1～4 in the medicine of preparation treatment venereal disease.
6, resistance disease-specific composite yolk antibody according to claim 5 is in the application of treatment on the venereal disease, it is characterized in that prepared composite yolk antibody is equipped with 99.98～20% auxiliary material by 0.02～80% quality percentage composition makes the sick combination preparation of resistance.
7, the application of resistance disease-specific composite yolk antibody according to claim 6 on the treatment venereal disease is characterized in that described combination preparation is the sick washing lotion of resistance.
8, the application of resistance disease-specific composite yolk antibody according to claim 6 on the treatment venereal disease is characterized in that described combination preparation is the sick sprays of resistance.
9, the application of resistance disease-specific composite yolk antibody according to claim 6 on the treatment venereal disease is characterized in that described combination preparation is the sick ointment of resistance.
10, the application of resistance disease-specific composite yolk antibody according to claim 6 on the treatment venereal disease is characterized in that described combination preparation is the sick effervescent tablet of resistance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031396879A CN1477127A (en) | 2003-07-03 | 2003-07-03 | Anti-venerism specific compound vitelline antibody and its application for curing venerism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031396879A CN1477127A (en) | 2003-07-03 | 2003-07-03 | Anti-venerism specific compound vitelline antibody and its application for curing venerism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1477127A true CN1477127A (en) | 2004-02-25 |
Family
ID=34155061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031396879A Pending CN1477127A (en) | 2003-07-03 | 2003-07-03 | Anti-venerism specific compound vitelline antibody and its application for curing venerism |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1477127A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103599076A (en) * | 2013-12-03 | 2014-02-26 | 济南大东农生物技术有限公司 | High-activity poultry antibody effervescent granular preparation and preparation method thereof |
| CN101328219B (en) * | 2008-07-09 | 2014-09-24 | 深圳雅臣生物科技有限公司 | Nano liposome anti-HPV, gynecological inflammation pathogen specific compound IgY and combined preparation thereof |
| CN108653729A (en) * | 2018-08-27 | 2018-10-16 | 广州汇高生物科技有限公司 | A kind of vaginal foam agent and its application |
| CN109010825A (en) * | 2018-08-27 | 2018-12-18 | 广州汇高生物科技有限公司 | A kind of vagina in-situ gel preparation and its preparation method and application |
| CN109053881A (en) * | 2018-08-27 | 2018-12-21 | 广州汇高生物科技有限公司 | A kind of special yolk polyclonal antibody and its application |
-
2003
- 2003-07-03 CN CNA031396879A patent/CN1477127A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101328219B (en) * | 2008-07-09 | 2014-09-24 | 深圳雅臣生物科技有限公司 | Nano liposome anti-HPV, gynecological inflammation pathogen specific compound IgY and combined preparation thereof |
| CN103599076A (en) * | 2013-12-03 | 2014-02-26 | 济南大东农生物技术有限公司 | High-activity poultry antibody effervescent granular preparation and preparation method thereof |
| CN103599076B (en) * | 2013-12-03 | 2015-12-30 | 济南大东农生物技术有限公司 | A kind of high-activity poultry antibody effervescent granular preparation and preparation method thereof |
| CN108653729A (en) * | 2018-08-27 | 2018-10-16 | 广州汇高生物科技有限公司 | A kind of vaginal foam agent and its application |
| CN109010825A (en) * | 2018-08-27 | 2018-12-18 | 广州汇高生物科技有限公司 | A kind of vagina in-situ gel preparation and its preparation method and application |
| CN109053881A (en) * | 2018-08-27 | 2018-12-21 | 广州汇高生物科技有限公司 | A kind of special yolk polyclonal antibody and its application |
| CN108653729B (en) * | 2018-08-27 | 2021-11-19 | 广州汇高生物科技有限公司 | Vaginal foaming agent and application thereof |
| CN109010825B (en) * | 2018-08-27 | 2021-11-19 | 广州汇高生物科技有限公司 | Vagina in-situ gel preparation and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101328219B (en) | Nano liposome anti-HPV, gynecological inflammation pathogen specific compound IgY and combined preparation thereof | |
| CN101948536B (en) | Porcine transmissible gastroenteritis virus (PTGEV) and porcine epidemic diarrhea virus (PEDV) dual yolk antibody and preparation method thereof | |
| CN101357229A (en) | Production technique of immunoglobulin compounding agent capable of preventing and treating pig diarrhea | |
| CN1207005C (en) | Rabbit skin containing bioactive substance and its use | |
| CN102302778A (en) | Preparation method and application of traditional Chinese medicinal immunoglobulin compound preparation | |
| CN101475626A (en) | Method for extracting transfer factor from pig spleen | |
| CN1153574C (en) | Use of bacterial cell wall extracts for treating, preventing or removing protozoa or parasitism diseases | |
| CN1454901A (en) | Gynaecological anti-infective specificity IgY and its combined preparation | |
| CN1206243C (en) | Yolk antibody and antigen of pig's infective enterogastritis virus and its preparing process | |
| CN1485343A (en) | Production method of specific IgY for venereal disease and its combined preparation | |
| CN101310730A (en) | Use of clostridium butyricum for preparing microbiological preparation for preventing and curing atrophic arthritis, ankylosing spondylitis | |
| CN1477127A (en) | Anti-venerism specific compound vitelline antibody and its application for curing venerism | |
| KR101373770B1 (en) | Pharmaceutical composition comprising Angelica dahurica Bentham et Hook extract for preventing or treating infectious disease of Enterohamorrhagic Escherichia coli | |
| CN1411833A (en) | Pure Chinese medicine preparation | |
| CN101259271A (en) | Anti-diarrhea yolk antibody feed additive and injection for goat and preparation thereof | |
| CN101074260A (en) | Production of hygrophilous monospermous bacterium main-protective antigen univalent and multivalent vitelline antibody and use in aquatic animal | |
| CN111228482B (en) | Canine parvovirus egg yolk antibody and phage composite preparation and application thereof | |
| CN101856495B (en) | Medical composition and mixture for treating chicken infectious bursal disease and preparation method thereof | |
| CN102731652A (en) | Preparation method of nanoliposome anti-bovine mastitis drug-resistant pathogenic bacteria specific composite IgY and its preparation | |
| CN1132631C (en) | Veterinary medicine for treating infective serositis of duck and its preparing process | |
| CN1911444A (en) | Typhoid, paratyphoid ectoblast protein vaccine | |
| CN112079916B (en) | Canine parvovirus egg yolk antibody and preparation method thereof | |
| CN1569896A (en) | Preparation of composite specific yelk antibody igy against cutaneous infection and its use in treatment of cutaneous infection | |
| TWI511743B (en) | Antiserum, neutralizing antibody, and pharmaceutical composition containing the same | |
| CN1657541A (en) | Process for preparating specificity complex IgY of anti coxsackie virus myocarditis and its compound preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |